Edition:
United States

Amphastar Pharmaceuticals Inc (AMPH.OQ)

AMPH.OQ on NASDAQ Stock Exchange Global Select Market

18.60USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$18.60
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
89,627
52-wk High
$21.75
52-wk Low
$12.06

Select another date:

Wed, Nov 29 2017

BRIEF-Amphastar Announces Approval For Medroxyprogesterone Acetate Injectable Suspension, USP

* AMPHASTAR ANNOUNCES APPROVAL FOR MEDROXYPROGESTERONE ACETATE INJECTABLE SUSPENSION, USP

BRIEF-Amphastar Pharma reports results for three months ended Sept

* Amphastar Pharmaceuticals reports financial results for the three months ended September 30, 2017

BRIEF-Amphastar Pharmaceuticals receives FDA approval for sodium bicarbonate injection

* Amphastar Pharmaceuticals receives FDA approval for sodium bicarbonate injection

BRIEF-Amphastar Pharmaceuticals reports Q2 earnings per share $0.04

* Amphastar Pharmaceuticals reports financial results for the three months ended june 30, 2017

BRIEF-Amphastar announces jury verdict in litigation against Momenta Pharmaceuticals and Sandoz Inc

* Amphastar announces jury verdict in patent litigation against Momenta Pharmaceuticals Inc and Sandoz Inc

U.S. jury sides with Amphastar over Momenta in drug patent trial

BOSTON A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox.

U.S. jury sides with Amphastar over Momenta in drug patent trial

BOSTON A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox.

UPDATE 2-U.S. jury sides with Amphastar over Momenta in drug patent trial

BOSTON, July 21 A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox.

U.S. jury sides with Amphastar over Momenta in drug patent trial

BOSTON, July 21 Amphastar Pharmaceuticals Inc on Friday won a trial in a lawsuit claiming that the drugmaker through its production of a generic version of the blood-thinner Lovenox infringed a patent held by Momenta Pharmaceuticals Inc.

Momenta seeks $938 million from Amphastar at drug patent trial's end

A lawyer for Momenta Pharmaceuticals Inc urged a federal jury on Thursday to force Amphastar Pharmaceuticals Inc to pay $938 million for infringing a patent the drugmaker held through its production of a generic version of the blood-thinner Lovenox.

Select another date: